MZMichael Zhu

Michael Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Zhu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring online discussions in men with testicular cancer: a qualitative and sentiment analysis of Reddit posts

    by Matthew Wysocki, Nick Winokur, Michael Zhu, Justin Loloi, Richard S. Matulewicz

    Purpose The goal of this study is to better understand the content and tone of discussions that men with testicular cancer are having on the testicular cancer subreddit and to explore any unmet survivorship needs or concerns in men with testicular cancer. Methods A total of 500 posts were randomly selected from the subreddit r/testicularcancer, spanning April to June 2023. Using qualitative analysis, the posts were categorized based on themes such as treatment options, side effects, personal experiences, advice-seeking, emotional sharing, men’s health issues, and expressions of gratitude. Sentiment analysis was performed using the validated tool VADER. Metrics collected included age, number of upvotes, cancer stage, pathology, and treatment discussed. Results The predominant themes were seeking advice (66.8%), sharing personal journeys (58.8%), and sharing emotions (32.6%). Less frequently discussed themes included treatment options (15.2%), side effects (14.2%), and men’s health issues (9.8%). Overall, the majority of posts (262) had a positive sentiment, with an average VADER score of all posts of 0.12. Conclusion Men with testicular cancer prioritize discussing personal experiences and emotional challenges on Reddit, indicating unmet emotional support needs in clinical settings. Despite a lower frequency of posts on men’s health issues, these topics garnered interest, highlighting potential barriers to discussing sexual health, even in online forums. Healthcare providers should recognize the value of these forums and consider referring patients to peer support resources while addressing emotional and sexual health concerns more comprehensively in clinical practice. Future research should explore targeted interventions to address the specific needs identified in these online discussions.


  • Open Access

    Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel

    by Andrewe L. Baca, Rutul D. Patel, Kevin Labagnara, Benjamin Green, Michael Zhu, Kavita Gupta, Beth Edelblute, Andrea A. Asencio, Deep Sharma, Wei Chen, et al.

    We aimed to characterize the underlying genetics of kidney stone disease (KSD) in an urban and diverse population using the Natera Renasight genetic panel. This was a single-center prospective study of high-risk KSD patients, defined as recurrent stone formers or those with a family history with KSD. Buccal saliva DNA samples were collected with the commercially available Natera Renasight genetic panel and were analyzed using next-generation sequencing. The panel assesses 385 kidney disease related genes, including 45 linked to KSD. One hundred eleven high-risk KSD patients were enrolled. The majority were female (56%) with a median age of 50 (IQR 39.5–59.5), compromising a diverse ethnic background with 62% Hispanic, 23% White and 11% Black. Patients had median 3 (IQR 2–5) lifetime stone episodes, and 41% had family history of KSD. Genetic analysis was possible for 105 patients (95%). Eight (8%) had positive tests with only one patient found to have a pathogenic mutation associated with KSD (SLC7A9, cystinuria). The other 7 positive tests included amyloidosis (TTR, N = 3), Alport syndrome (COL4A3, N = 2), polycystic kidney disease (PKD1, N = 1), and susceptibility to ESRD (APOL1, N = 1). Patients with positive tests were more likely to have chronic kidney disease (38% vs 5%, p < 0.01), gout (13% vs 1%, p = 0.02) and carbonate apatite stones (38% vs 7%, p < 0.01). Our study sheds light on genetic factors of KSD in a diverse patient population. The results suggest that KSD is unlikely monogenetic in nature, but is more likely due to a complex interplay of polygenetic and environmental influences. Genetic testing may be most useful in KSD patients with chronic kidney disease.


  • Open Access

    Risk factors for reoperation of inflatable penile prosthesis among an ethnically diverse urban population in a high-volume center

    by Noah Hawks-Ladds, Mustufa Babar, Kevin Labagnara, Justin Loloi, Rutul D. Patel, Arshia Aalami Harandi, Michael Zhu, Azizou Salami, Pedro Maria

    Inflatable penile prosthesis (IPP) is a surgical treatment for erectile dysfunction refractory to medical therapy or for those who desire permanent treatment. Complications like mechanical failure and infection may necessitate reoperation, and patients with certain risk factors remain predisposed to reoperation. We retrospectively analyzed 530 patients undergoing primary IPP implantation at a large, urban, multiethnic hospital with a high volume of IPP implantations. Primary outcomes were reoperation due to any reason and reoperation due to infection. Patient characteristics and intraoperative factors were compared between those requiring reoperation and those not requiring reoperation. Overall, 12.1% of patients underwent reoperation, primarily due to infection, with a median time to reoperation of 4 months. Analysis revealed an increased likelihood of reoperation with Peyronie’s disease (OR = 2.47), hemoglobin A1c over 8 (OR = 2.25), active smoking (OR = 2.75), and estimated blood loss (EBL) ≥ 25cc (OR = 2.45). A decreased likelihood of reoperation was observed when Arista™ powder was used intraoperatively (OR = 0.38). Reoperation specifically due to infection was associated with an infrapubic approach (OR = 2.56) and hypertension (OR = 9.12). Our findings confirm smoking and diabetes as risk factors for reoperation, while also providing insights into factors like estimated blood loss and Arista™ powder use. However, long-term survival rates were limited by loss to follow-up. (Clinical trial registration N/A).


  • Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

    by Noah Hawks-Ladds, Marc-Mina Tawfik, Mustufa Babar, Michael Zhu, Justin Loloi, Kevin Labagnara, Rahman Sayed, Azizou Salami, Matthew Ines, Nazifa Iqbal, et al.

    Water vapor thermal therapy (WVTT) is a minimally invasive therapy designed to treat lower urinary tract symptoms associated with benign prostatic hyperplasia. Long-term outcomes with large (>80 cc) and small ( 80 cc. Outcome measures, including International Prostate Symptom Score, quality of life, International Index of Erectile Function, medication usage, and adverse events, were analyzed at baseline and at 1-, 3-, 6-, 12-, 24-, 36-, and/or 48-month follow-up. Two hundred fifty-two patients met inclusion; 35 (13.9%) had PVs < 30 cc, 196 (77.8%) had PVs 30 to 80 cc, and 21 (8.3%) had PVs > 80 cc. Most patients were Asian (33.7%) or non-Hispanic Black (29.4%). International Prostate Symptom Score and quality of life improved in all cohorts from baseline at all follow-ups (all P < .05), with no differences between cohorts. International Index of Erectile Function-Orgasmic Function and -Erectile Function domains improved in 30 to 80 cc patients at 48 months. Alpha blocker and/or 5-alpha reductase inhibitor usage decreased at all follow-ups in < 30 cc and 30 to 80 cc patients and remained durable to only 6 months for > 80 cc patients. No significant differences in adverse events or reoperation rates were observed between cohorts. Our study suggests WVTT to be efficacious, durable, and safe in managing lower urinary tract symptoms across PVs, although PV > 80 cc patients may require benign prostatic hyperplasia medication at long-term follow-up. Further research is desired to clarify WVTT's role regarding sexual function and in treating men with larger PVs.


  • Open Access

    Correction: Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men

    by Michael Zhu, Mustufa Babar, Noah Hawks-Ladds, Marc-Mina Tawfik, Justin Loloi, Kevin Labagnara, Rahman Sayed, Kevin Tang, Azizou Salami, Sandeep Singh, et al.

  • Open Access

    Pudendal nerve block decreases narcotic requirements and time spent in post-anesthesia care units in patients undergoing primary inflatable penile prosthesis implantation

    by Michael Zhu, Kevin Labagnara, Justin Loloi, Mustufa Babar, Arshia Aalami Harandi, Azizou Salami, Ari Bernstein, Jonathan Davila, Meenakshi Davuluri, Charbel Chalouhy, et al.

    Efforts to minimize narcotic usage following inflatable penile prosthesis (IPP) implantation are vital, considering the current opioid epidemic in the United States. We aimed to determine whether pudendal nerve block (PNB) utilization in a multiethnic population undergoing primary IPP implantation can decrease rates of post-operative opiate usage. A single-institution, retrospective study was conducted on patients who underwent primary IPP implantation between December 2015 and June 2022. PNB usage and intra- and post-operative outcomes were analyzed using multivariate binary logistic regression. 449 patients were included, with 373 (83.1%) in the PNB group. Median time (minutes) spent in the post-anesthesia care unit (PACU) (1499 [119–198] vs. 235 [169–322], p < 0.001) was significantly lower in the PNB group. There were no significant differences in intra-operative and PACU morphine milligram equivalents or post-operative safety outcomes between groups. However, fewer patients in the PNB group called for pain medications post-operatively (10.2% vs 19.7%, p = 0.019). Multivariate analysis revealed a significantly decreased operative time (B −6.23; 95%CI −11.28, −1.17; p = 0.016) and decreased time in recovery (B: −81.62; 95%CI: −106.49, −56.76, p < 0.001) in the PNB group. PNB decreases post-operative opioid analgesic requirements and time spent in PACU in patients undergoing a primary IPP implantation and thus may represent an attractive, non-opioid adjunct.


  • Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men

    by Michael Zhu, Mustufa Babar, Noah Hawks-Ladds, Marc-Mina Tawfik, Justin Loloi, Kevin Labagnara, Rahman Sayed, Kevin Tang, Azizou Salami, Sandeep Singh, et al.

    Background Management of urinary symptoms in elderly patients with benign prostatic hyperplasia (BPH) is complex given challenges with medications and invasive surgeries. Rezum, a minimally invasive water vapor therapy, is an emerging alternative. We compare real-world Rezum outcomes between young and elderly patients over 4 years. Methods We retrospectively analyzed a multiethnic population treated with Rezum at a single center between 2017–2019. Patients were stratified into young (t-tests, Chi-squared, or Mann-Whitney U tests. Changes in outcomes were assessed using Wilcoxon signed-rank tests, stratified by age. Results 256 patients – 146 (57%) young and 110 (43%) elderly – were included. The majority were Asian (33.2%) or non-Hispanic Black (28.9%). Significant improvements were observed in the combined cohort at 4-years in IPSS, QoL, and Qmax when compared to baseline (all p < 0.05). Between the age cohorts, there were no significant differences in IPSS, QoL, or Qmax at any follow-up. Within both cohorts, significant improvements in IPSS and QoL were found from baseline to all follow-ups. In the young cohort, Qmax was significantly improved from baseline to all follow-ups while in the elderly cohort, this was observed only at the 3-month follow-up. No significant differences in AEs or regret was found between cohorts. There was no significant difference in 4-year surgical retreatment rates between cohorts (elderly 4.0% vs young 4.4%, p = 0.86). Conclusions There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men.


  • Predictors of Timely and Delayed Urological Evaluation Following Referral for Elevated Prostate-specific Antigen in a Diverse, Urban, High-risk Population

    by Rutul D. Patel, Michael Zhu, Priya Dave, Ilir Agalliu, Quoc-Dien Trinh, Kara L. Watts

    Introduction:This study aimed to evaluate predictors of timely urological evaluation among men referred for initial elevated PSA in a diverse, high-risk, urban community.Methods:We conducted a retrospective cohort study of all men aged 50+ referred to urology within our healthcare network between January 2018 and December 2021 for initial elevated PSA. Time to initial urological evaluation was categorized as timely (within 4 months of referral), late (after 4 months), or absent (no urology evaluation). Demographic and clinical variables were abstracted. A multivariable multinomial logistic regression model was conducted to identify predictors of timely vs late vs absent urological evaluation controlling for age, referral year, household income, distance to care, and PSA at referral.Results:A total of 1,335 men met inclusion criteria; 589 (44.1%), 210 (15.7%), and 536 (40.1%) had timely, late, and absent urological evaluation, respectively. The majority were non-Hispanic Black (46.7%), English-speaking (84.0%), and married (54.6%). Median time to initial urological evaluation differed significantly between timely and late groups (16 vs 210 days, P < .001). Multivariable logistic regression revealed the following to be significant predictors of timely urological evaluation: non-Hispanic Black (OR=1.59, P = .03), Hispanic (OR=2.07, P = .001), Spanish-speaking (OR=1.44, P = .03), or former-smokers (OR=1.31, P = .04).Conclusions:In our diverse community, men who are non-Hispanic White or English-speaking have a decreased odds of timely urological evaluation after a referral for elevated PSA in our diverse patient population. Our study underscores cohorts that may benefit from implementation of institutional safeguards such as patient navigation systems to facilitate and ensure appropriate follow-up upon referral for elevated PSA.


  • Association between respiratory disease and stress urinary incontinence: An analysis of the 2015−2020 National Health and Nutrition Examination Survey

    by Michael Zhu, Jasper Sim, Chihiro Okada, Joseph Kim, Nitya Abraham

    Introduction: There is a logical association between chronic obstructive pulmonary disease (COPD) or asthma with stress urinary incontinence (SUI), given the propensity for coughing which increases intra‐abdominal pressure. However, there are few studies examining the association between COPD or asthma and specifically SUI. We aimed to utilize the National Health and Nutrition Examination Survey (NHANES) data from 2015 to 2020 to measure the association between respiratory diseases like COPD and asthma with SUI.Methods: Data was collected from NHANES, a database representative of the United States population. Participants were included if they were female, older than 20 years, and completed the incontinence survey question. Self‐reported history of asthma and COPD diagnosis from a physician, as well as history of incontinence associated with activities such as coughing, lifting, or exercise, were collected. Characteristics of participants were compared using χ2 and Student t‐tests. Multivariable logistic regression was performed using a multimodel approach to adjust for sociodemographic and health‐related covariates.Results: A total of 9059 women were included in this study. 42.13% reported an episode of SUI in the past year, 6.29% had a COPD diagnosis, and 11.86% had an asthma diagnosis. In the unadjusted analysis, participants with COPD were more likely to report SUI (odds ratio [OR] 3.42, 95% confidence interval [CI] 2.13−5.49, p < 0.001); this association persisted on multivariable analysis (OR 2.87, 95% CI 1.46−5.60, p = 0.003). There was no significant association between asthma and SUI in the unadjusted (OR 1.15, 95% CI 0.96−1.38, p = 0.14) or adjusted model (OR 1.18, 95% CI 0.86−1.60, p = 0.30).Conclusion: Although a strong association between COPD and SUI was observed, an analogous one was not found between asthma and SUI. Chronic cough may be more difficult to control with treatment or more common in those with COPD than asthma, explaining this difference. Future research should continue to explore drivers for SUI in large populations to dispel or affirm historically assumed SUI risk factors.